|

Belzutifan Clinical Trials

12 actively recruiting trials across 7 locations

No change since June 2026

Also known as: 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile, C17H12F3NO4S, MK-6482, MK-6482, PT2977, WELIREG, NSC#825217 +6 more

Pipeline

Phase 1: 2Phase 2: 6Phase 3: 3Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC5
  • M.D. Anderson Cancer Center2
  • NYU Langone Health1
  • José Claudio Casali da Rocha1
  • HiberCell, Inc.1

Indications

  • Cancer12
  • Pheochromocytoma/Paraganglioma3
  • Von Hippel-Lindau Disease3
  • Renal Cell Carcinoma3
  • Clear Cell Renal Cell Carcinoma2

Other3 trials

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Phase 3
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
Phase 2
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Phase 2

Boston, Massachusetts2 trials

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Brigham and Women's Hospital

Phase 2
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Beth Israel Deaconess Medical Center ( Site 0107)

Phase 3

Houston, Texas2 trials

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

MD Anderson Cancer Center

Phase 2
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

The University of Texas M. D. Anderson Cancer Center

Phase 2

Anchorage, Alaska1 trial

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Alaska Oncology and Hematology ( Site 0133)

Phase 3

Tucson, Arizona1 trial

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

University of Arizona Cancer Center

Phase 1

Los Angeles, California1 trial

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Cedars-Sinai Medical Center ( Site 0110)

Phase 2

San Francisco, California1 trial

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

UCSF Medical Center at Mission Bay ( Site 5008)

Phase 1/2

New York, New York1 trial

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

NYU Langone Health

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.